Figure 1From: Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximabStudy design. K-RAS (and then RAS) wild type colorectal cancer patients candidates to receive treatment with cetuximab were prospectively assigned to the favourable or unfavourable group on the basis of their molecular profile. All patients were then treated with cetuximab in combination with chemotherapy. Treating physicians were blind to patients allocation. RR was the primary endpoint of the study.Back to article page